Biomarker Identification for Bladder Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Bladder Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/14/2017 |
| Start Date: | January 21, 2014 |
| End Date: | November 30, 2018 |
| Contact: | Ohio State University Comprehensive Cancer Center |
| Email: | Jamesline@osumc.edu |
| Phone: | 1-800-293-5066 |
To develop a simple blood and urine test that we would perform before patients start their
treatment to predict the risk that their bladder cancer might come back. To develop this
test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer
patients and follow them closely during and after treatment. This will include looking for
changes in proteins and genes that might play a role in bladder cancer biology. The
investigators will then compare the information obtained from the studies of blood, urine
and cancer tissue between patients that are cured and those whose cancer comes back. The
knowledge about these differences between patients can then potentially be used to develop a
blood or urine test to tell us who has a high risk for having bladder cancer come back.
treatment to predict the risk that their bladder cancer might come back. To develop this
test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer
patients and follow them closely during and after treatment. This will include looking for
changes in proteins and genes that might play a role in bladder cancer biology. The
investigators will then compare the information obtained from the studies of blood, urine
and cancer tissue between patients that are cured and those whose cancer comes back. The
knowledge about these differences between patients can then potentially be used to develop a
blood or urine test to tell us who has a high risk for having bladder cancer come back.
Inclusion Criteria:
- Adult patients ≥18 years old.
- Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.
- Patients undergoing cystoscopy without cancer suspicion.
- Ability to give an informed consent.
Exclusion Criteria:
- Patients receiving concurrent therapy for a second malignancy.
- < 18 years old.
- Inability to give an informed consent.
We found this trial at
1
site
Click here to add this to my saved trials
